Literature DB >> 16426002

Development of a clinical assay to evaluate toll-like receptor function.

Raquel P Deering1, Jordan S Orange.   

Abstract

Toll-like receptors (TLRS) recognize pathogen-associated molecular patterns to enable innate immune responses. A number of genetic defects influencing the function of these receptors have been identified and are associated with recurrent and/or severe infection. Our goal was to develop a reproducible assay of TLR function in order to evaluate patients with recurrent infection who would be suspected of having a genetic defect affecting TLR signaling. We chose to study peripheral blood mononuclear cells (PBMCS) to avoid potential influences of soluble factors contained in whole blood, and we utilized ligands for TLRS 1/2, 2/6, 3, 4, 5, 6, 7, and 9. Tumor necrosis factor (TNF) production in PBMC supernatants was measured by an enzyme-linked immunosorbent assay after TLR ligand stimulation and was dependent on gene transcription and NF-kappaB activation. Some variables affecting the assay were assessed, including the effects of: blood anticoagulant, serum-containing media, incubation time, ligand storage, blood storage time, and cell cryopreservation. By using optimized assay conditions, effective concentrations of individual ligands and mean responses to those ligands were established for healthy control donors. Finally, three patients with a mutation in the IKBKG gene, encoding the NF-kappaB essential modulator (NEMO) protein, were evaluated as disease controls and were almost uniformly below the standard deviation of healthy donors for all ligands tested. Although a number of variables influence TLR ligand-induced TNF responses, this assay can be optimized for potential clinical use to screen patients with primary immunodeficiencies affecting TLR function.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16426002      PMCID: PMC1356616          DOI: 10.1128/CVI.13.1.68-76.2006

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  25 in total

Review 1.  Recognition of microbial infection by Toll-like receptors.

Authors:  Elizabeth Kopp; Ruslan Medzhitov
Journal:  Curr Opin Immunol       Date:  2003-08       Impact factor: 7.486

Review 2.  Toll-like receptor signalling.

Authors:  Shizuo Akira; Kiyoshi Takeda
Journal:  Nat Rev Immunol       Date:  2004-07       Impact factor: 53.106

3.  Deficient natural killer cell cytotoxicity in patients with IKK-gamma/NEMO mutations.

Authors:  Jordan S Orange; Scott R Brodeur; Ashish Jain; Francisco A Bonilla; Lynda C Schneider; Roberto Kretschmer; Samuel Nurko; Wendy L Rasmussen; Julia R Köhler; Stephen E Gellis; Betsy M Ferguson; Jack L Strominger; Jonathan Zonana; Narayanaswamy Ramesh; Zuhair K Ballas; Raif S Geha
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

4.  Selective impairment of TLR-mediated innate immunity in human newborns: neonatal blood plasma reduces monocyte TNF-alpha induction by bacterial lipopeptides, lipopolysaccharide, and imiquimod, but preserves the response to R-848.

Authors:  Ofer Levy; Kol A Zarember; Rene M Roy; Colette Cywes; Paul J Godowski; Michael R Wessels
Journal:  J Immunol       Date:  2004-10-01       Impact factor: 5.422

5.  The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation.

Authors:  Jordan S Orange; Ashish Jain; Zuhair K Ballas; Lynda C Schneider; Raif S Geha; Francisco A Bonilla
Journal:  J Allergy Clin Immunol       Date:  2004-04       Impact factor: 10.793

6.  Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia.

Authors:  Jordan S Orange; Ofer Levy; Scott R Brodeur; Konrad Krzewski; Rene M Roy; Julie E Niemela; Thomas A Fleisher; Francisco A Bonilla; Raif S Geha
Journal:  J Allergy Clin Immunol       Date:  2004-09       Impact factor: 10.793

7.  The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily.

Authors:  Florian Heil; Parviz Ahmad-Nejad; Hiroaki Hemmi; Hubertus Hochrein; Franziska Ampenberger; Tanja Gellert; Harald Dietrich; Grayson Lipford; Kiyoshi Takeda; Shizuo Akira; Hermann Wagner; Stefan Bauer
Journal:  Eur J Immunol       Date:  2003-11       Impact factor: 5.532

8.  Primary immunodeficiency to pneumococcal infection due to a defect in Toll-like receptor signaling.

Authors:  Andrew J Currie; Donald J Davidson; Gregor S D Reid; Simi Bharya; Kelly L MacDonald; Rebecca S Devon; David P Speert
Journal:  J Pediatr       Date:  2004-04       Impact factor: 4.406

9.  Pyogenic bacterial infections in humans with IRAK-4 deficiency.

Authors:  Capucine Picard; Anne Puel; Marion Bonnet; Cheng-Lung Ku; Jacinta Bustamante; Kun Yang; Claire Soudais; Stéphanie Dupuis; Jacqueline Feinberg; Claire Fieschi; Carole Elbim; Remi Hitchcock; David Lammas; Graham Davies; Abdulaziz Al-Ghonaium; Hassan Al-Rayes; Sulaiman Al-Jumaah; Sami Al-Hajjar; Ibrahim Zaid Al-Mohsen; Husn H Frayha; Rajivi Rucker; Thomas R Hawn; Alan Aderem; Haysam Tufenkeji; Soichi Haraguchi; Noorbibi K Day; Robert A Good; Marie-Anne Gougerot-Pocidalo; Adrian Ozinsky; Jean-Laurent Casanova
Journal:  Science       Date:  2003-03-13       Impact factor: 47.728

10.  Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections.

Authors:  Andrei E Medvedev; Arnd Lentschat; Douglas B Kuhns; Jorge C G Blanco; Cindy Salkowski; Shuling Zhang; Moshe Arditi; John I Gallin; Stefanie N Vogel
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  14 in total

1.  Variables to be controlled in the assessment of blood innate immune responses to Toll-like receptor stimulation.

Authors:  Darren Blimkie; Edgardo S Fortuno; Howard Yan; Patricia Cho; Kevin Ho; Stuart E Turvey; Arnaud Marchant; Stanislas Goriely; Tobias R Kollmann
Journal:  J Immunol Methods       Date:  2011-01-28       Impact factor: 2.303

2.  Polychromatic flow cytometric high-throughput assay to analyze the innate immune response to Toll-like receptor stimulation.

Authors:  Kirstin Jansen; Darren Blimkie; Jeff Furlong; Adeline Hajjar; Annie Rein-Weston; Juliet Crabtree; Brian Reikie; Christopher Wilson; Tobias Kollmann
Journal:  J Immunol Methods       Date:  2008-05-16       Impact factor: 2.303

3.  Congenital alterations of NEMO glutamic acid 223 result in hypohidrotic ectodermal dysplasia and immunodeficiency with normal serum IgG levels.

Authors:  Gital Karamchandani-Patel; Eric P Hanson; Rushani Saltzman; C Eve Kimball; Ricardo U Sorensen; Jordan S Orange
Journal:  Ann Allergy Asthma Immunol       Date:  2011-05-04       Impact factor: 6.347

4.  BAY 41-2272, a soluble guanylate cyclase agonist, activates human mononuclear phagocytes.

Authors:  P V Soeiro-Pereira; A Falcai; C A Kubo; E B Oliveira-Júnior; O C Marques; E Antunes; A Condino-Neto
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  Toll-like receptor 7 and 9 defects in common variable immunodeficiency.

Authors:  Joyce E Yu; Adina K Knight; Lin Radigan; Thomas U Marron; Li Zhang; Silvia Sanchez-Ramón; Charlotte Cunningham-Rundles
Journal:  J Allergy Clin Immunol       Date:  2009-07-09       Impact factor: 10.793

6.  Immune dysregulation in severe influenza.

Authors:  Meredith L Heltzer; Susan E Coffin; Kelly Maurer; Asen Bagashev; Zhe Zhang; Jordan S Orange; Kathleen E Sullivan
Journal:  J Leukoc Biol       Date:  2009-06       Impact factor: 4.962

7.  LPS and poly I:C induce chromatin modifications at a novel upstream region of the IL-23 p19 promoter.

Authors:  Stacey Garrett; Michael C Fitzgerald; Kathleen E Sullivan
Journal:  Inflammation       Date:  2008-08       Impact factor: 4.092

8.  IKBKG (nuclear factor-kappa B essential modulator) mutation can be associated with opportunistic infection without impairing Toll-like receptor function.

Authors:  Bryn H Salt; Julie E Niemela; Rahul Pandey; Eric P Hanson; Raquel P Deering; Ralph Quinones; Ashish Jain; Jordan S Orange; Erwin W Gelfand
Journal:  J Allergy Clin Immunol       Date:  2008-01-07       Impact factor: 10.793

Review 9.  Diagnostic Tools for Inborn Errors of Human Immunity (Primary Immunodeficiencies and Immune Dysregulatory Diseases).

Authors:  Annely M Richardson; Ann M Moyer; Linda Hasadsri; Roshini S Abraham
Journal:  Curr Allergy Asthma Rep       Date:  2018-02-22       Impact factor: 4.806

10.  Lack of effect of glutamine administration to boost the innate immune system response in trauma patients in the intensive care unit.

Authors:  Jon Pérez-Bárcena; Catalina Crespí; Verónica Regueiro; Pedro Marsé; Joan M Raurich; Jordi Ibáñez; Abelardo García de Lorenzo-Mateos; José A Bengoechea
Journal:  Crit Care       Date:  2010-12-24       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.